Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of silevimig injection plus human rabies vaccine in children and adolescents with suspected category III rabies exposure
CTR20253293Phase 3Active
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of silevimig in rabies, sponsored by Zhixiang Jintai. Started Sep 2025; status: active.
02
Drugs
silevimig
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20253293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253293.